-

Shareholder Alert: Robbins LLP Announces that Evolus, Inc. (EOLS) is Being Sued for Misleading Shareholders

SAN DIEGO & NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Evolus, Inc. (NASDAQ: EOLS) has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between February 1, 2019 and July 6, 2020. Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. Evolus' sole product is Jeuveau™, a purified botulinum toxin indicated for the temporary improvement in the appearance of moderate to severe frown lines in adults, which competes with Botox®.

If you suffered a loss due to Evolus, Inc.'s misconduct, click here.

Evolus, Inc. (EOLS) Accused of Misappropriating Trade Secrets

According to the complaint, beginning in February 2019, Evolus began a campaign in which it promoted Jeuveau™ as a proprietary formulation of the botulinum toxic type A complex, purportedly developed by a Korean bioengineering company through years of clinical research. On July 6, 2020, the investing public learned the truth when the U.S. International Trade Commission ("ITC") issued its Initial Final Determination in a case brought by Allergan and Medytox against Evolus, which claimed that Evolus stole trade secrets to develop Jeuveau. The ITC Judge determined that Evolus and its South Korean partner firm misappropriated the botulinum toxin and the manufacturing process that led to its development and manufacture. As a result, the ITC Judge recommended a ten-year long ban on Evolus' ability to import and sell Jeuveau in the United States. On this news, Evolus' stock dropped 37% in two days to close at $3.35 on July 8, 2020.

If you purchased Evolus, Inc. (EOLS) securities between February 1, 2019 and July 6, 2020, you have until December 15, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Evolus, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Alert: Robbins LLP Informs Investors of the Skechers U.S.A., Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Skechers U.S.A., Inc. insiders face allegations that they engaged in a fraudulent scheme to buy out shareholders at an artificially depressed price....

Robbins LLP Urges DAVA Stockholders Who Lost Money Investing in Endava plc to Contact the Firm for Information About Leading the Class Action Lawsuit 

SAN DIEGO--(BUSINESS WIRE)--Endava plc faces allegations that it misled investors regarding its accounting treatment of certain customer and supplier agreements....

Robbins LLP Urges AVXL Stockholders Who Lost Money Investing in Anavex Life Sciences Corp. to Contact the Firm for Information About Leading the Class Action  

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is investigating allegations that Anavex Life Sciences Corp. misled investors regarding its lack of adequate internal controls....
Back to Newsroom